Nanjing Leads Biolabs says Oblenio exercises LBL-051 license option, triggering USD 10 million fee

• Oblenio exercised its option to retain the worldwide license for LBL-051, triggering a one-time US$ 10 million payment.
• The move follows ongoing Phase Ia first-in-human dosing in Europe, supporting continued global clinical development planning.
• Preclinical results were already presented at EULAR 2026, indicating broad immune-cell depletion without cytokine release syndrome.
• The data suggested an immune “reset” profile that could support durable remission in refractory autoimmune diseases, without citing technical metrics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260820-12291280), on August 19, 2026, and is solely responsible for the information contained therein.